08:33 AM EDT, 10/17/2025 (MT Newswires) -- Achieve Life Sciences ( ACHV ) said Friday that it has received the US Food and Drug Administration's Commissioner's National Priority Voucher for cytisinicline to treat nicotine dependence for e-cigarette or vaping cessation.

The FDA also granted breakthrough therapy designation to cytisinicline for nicotine e-cigarette or vaping cessation, the company said, adding that the regulator has accepted the phase 3 trial design.

Cytisinicline showed clinical efficacy in the phase 2 Orca-V1 study, Achieve Life Sciences ( ACHV ) said.

Shares of the company were up 20% in recent Friday premarket activity.